Common Warts - Pipeline Insight, 2024

This ''Common Warts - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Common Warts Understanding

Warts are benign lesions that occur in the mucosa and skin. Warts are caused by the human papillomavirus (HPV), with over 100 types of HPV identified. HPV may occur at any site. The primary manifestations of HPV infection include common warts, genital warts, flat warts, deep palmoplantar warts (Myrmecia), focal epithelial hyperplasia, Epidermodysplasia verruciformis, and Plantar cysts. Warts may be transmitted by direct or indirect contact. Events that disrupt the normal epithelial barrier increase the likelihood of developing warts. Treatment may be difficult. Warts often resolve spontaneously within a few years. Some high-risk HPV subtypes are associated with malignancies, including types 6, 11, 16, 18, 31, and 35. Malignant transformation usually is seen in patients with genital warts and immunocompromised patients. HPV types 5, 8, 20, and 47 have oncogenic potential leading to epidermodysplasia verruciformis.

Common Warts - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Common Warts pipeline landscape is provided which includes the disease overview and Common Warts treatment guidelines. The assessment part of the report embraces, in depth Common Warts commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Common Warts collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts. The therapies under development are focused on novel approaches to treat/improve Common Warts.

Common Warts Emerging Drugs

Mavorixafor: X4 Pharmaceuticals
Mavorixafor as an oral, once-daily treatment for patients with WHIM syndrome. WHIM syndrome is a rare genetic primary immunodeficiency that results from “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.

VP-102: Verrica Pharmaceuticals
VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Common Warts: Therapeutic Assessment

This segment of the report provides insights about the Common Warts drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Common Warts

There are approx. 5+ key companies which are developing the therapies Common Warts. The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Common Warts: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Common Warts therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Common Warts drugs.

Common Warts Report Insights

• Common Warts Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Common Warts Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Common Warts drugs?
• How many Common Warts drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Common Warts?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Common Warts therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Common Warts and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Verrica Pharamceuticals
• X4 Pharmaceuticals
• Phio Pharmaceuticals
• Kino Pharma
• NIELSEN BioSciences

Key Products

• Cantharidin
• Mavorixafor
• Diphencyprone
• Kino Pharma Research Program
• Albicin

This product will be delivered within 2 business days.